Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead Raises HCV Guidance Slightly, Still Mum On M&A

Executive Summary

Gilead thinks 2017 HCV sales could reach as high as $9bn, still down from 2016, but higher than projected six months ago. Meanwhile, sales of TAF-based HIV regimens continue to grow and gain market share.


Related Content

Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth
Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta
Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy
First Sofosbuvir WHO Prequalification To Widen Access But How Far?
AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts